GLP-1 Agonists Improve Outcomes for Kidney Transplant Patients

Kidney transplantation (KT) is the optimal treatment for end-stage kidney disease, significantly improving survival and quality of life. However, long-term outcomes are often compromised by metabolic complications such as post-transplant diabetes mellitus (PTDM), obesity, dyslipidemia, and cardiovascular disease. These conditions not only increase the risk of graft loss and cardiovascular mortality but also complicate immunosuppressive therapy. This study aimed to systematically review and meta-analyze the clinical outcomes of glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in kidney transplant recipients to assess the efficacy and safety of these agents (a class of drugs that mimic the natural hormone glucagon-like peptide-1) in this vulnerable population.

The meta-analysis revealed significant improvements in metabolic parameters among kidney transplant recipients treated with GLP-1 RAs. Patients experienced a mean weight loss of 4.5 kg (p<0.001) and a reduction in HbA1c by 0.8% (p<0.001) compared to control groups. GLP-1 RA therapy was associated with a 35% reduction in the incidence of new-onset post-transplant diabetes mellitus (PTDM) (Relative Risk 0.65, 95% CI 0.48-0.88, p=0.005). Furthermore, systolic blood pressure decreased by 5 mmHg (p=0.01), and there was a 15% reduction in cardiovascular events (p=0.03). Renal function, as measured by eGFR, remained stable with no significant adverse impact (p=0.45), and the incidence of acute graft rejection was comparable between groups (p=0.62).